Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100

Thermo Fisher Scientific Inc. (TMO) EBITDA

Alert me on EBITDA

Thermo Fisher Scientific Inc.'s EBITDA for fiscal 2025 was $10.5B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $11.1B. Over the past ten years it has ranged from $4.0B (fiscal 2015) to $12.6B (fiscal 2021); the current reading is higher than 82% of that period. Thermo Fisher Scientific Inc. ranks 1st of 52 Diagnostics & Research companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $10.5B 0.78%
FY2024 $10.4B 1.76%
FY2023 $10.3B (12.82%)
FY2022 $11.8B (6.70%)
FY2021 $12.6B 24.72%
FY2020 $10.1B 47.27%
FY2019 $6.9B 13.57%
FY2018 $6.1B 21.17%
FY2017 $5.0B 18.43%
FY2016 $4.2B 4.77%

Quarterly newest first

Period EBITDA Change
Jun 2026 $2.9B 11.69%
Mar 2026 $2.6B (12.84%)
Dec 2025 $3.0B 14.69%
Sep 2025 $2.6B 3.17%
42 more quarters

Against its own ten years

Low $4.0B High $12.6B
Ten-year median $10.1B
Current reading's percentile 82

EBITDA against peers

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on TMO